Results 191 to 200 of about 545,656 (315)

Abstract 6822 Synergizing Generative AI and Computational Chemistry: Accelerating Discovery for Challenging Targets

Aravinda Munasinghe
openalex   +1 more source

Impact of targeted chemistries on maraging steel precipitation evolution observed using SANS and APT

, 2018
Veronica Gray, D.R. Galvin, P. Hill, M. Rawson, Karen Perkins   +4 more
openalex   +2 more sources

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

<i>In vitro</i> screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives <i>CDKN1</i> and <i>BBC3</i> expression to restore a p53-dependent cytotoxicity. [PDF]

J Enzyme Inhib Med Chem
Nannini S, Sieffert C, McGown A, Gao XY, Jarvis A, Kostakis GE, Galvacsi A, Kallay C, Moraru R, Baud MG, Mandel S, Balourdas DI, Joerger AC, Orvain C, Peschard S, Nion A, Mellitzer G, Lottiaux S, Spencer J, Gross I, Gaiddon C.   +20 more
europepmc   +1 more source

The Carbon-Cycle Window: A Phase-Chemistry Filter for Pre- Spectroscopic Biosignature Targeting

Kuldeep Kumar Pandit, Aayan Pandit, Vatsala pandit   +2 more
openalex   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Covalent Radiopharmaceuticals: Precision Imaging and Therapy for Cancer. [PDF]

Mol Pharm
Klauser PC, Wang L.
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Quantitative analysis of sequential nucleic acid elution from silica paramagnetic beads.

Analyst
Varon A, Schares J, Hsieh K, Downs B, Wang TH.   +4 more
europepmc   +1 more source

Design, synthesis, and biological evaluation of FXR/ASK1 dual-target modulators. [PDF]

Beilstein J Org Chem
Zhang X, Wang J, Zhao Z, Wang C, Ye Z, Ma WY, Xu JX, Zhang F.   +7 more
europepmc   +1 more source